Comparison of study data shows that the effects of oral butylscopolamine (Buscopan®) often occur after just 15 minutes

22.05.2015 13:35

Butylscopolamine is an active pharmaceutical ingredient used to treat pain and cramps in the gastrointestinal area. As part of Digestive Disease Week (DDW) in Washington on May 16, Boehringer Ingelheim presented three methodologically different scientific studies that show that the effect of orally administered butylscopolamine occurs within 15 minutes after taking two tablets (2 x 10 mg ) can be used.

Two of the three studies were conducted in randomized, double-blind clinical trials with Chinese and US patients. The third approach is a patient survey conducted in pharmacies that recorded experiences with butylscopolamine tablets and their onset of action in more than 1,400 German patients. In the clinical studies, butylscopolamine tablets were compared with placebo and with butylscopolamine capsules. Although each of the three studies used a different methodological approach, all showed similar results regarding an early onset of action of butylscopolamine tablets, which can occur as early as 15 minutes after ingestion.

Butylscopolamine is the active ingredient in Buscopan®, a medication from Boehringer Ingelheim used to treat abdominal cramps and abdominal pain.

“Many patients already trust Buscopan® and now we have the scientific evidence to prove how quickly oral butylscopolamine can help treat the unpleasant cramping pain in the abdomen and lower abdomen,” explained Dr. Tobias Mück, medical director of self-medication Germany at Boehringer Ingelheim. “A rapid onset of action in the treatment of these symptoms is a clear advantage for patients.”